Opinion|Videos|November 28, 2024
Importance of Genetic Counseling and Next-Generation Sequencing for Pediatric Epilepsy Diagnosis
Author(s)John Michael Schreiber, MD, FAES
Key Takeaways
- Genetic testing can identify mutations in pediatric epilepsy, guiding personalized treatment plans and improving patient outcomes.
- Caregivers must be informed about the benefits and limitations of genetic testing, including potential inconclusive results.
John Michael Schreiber, MD, describes how he counsels and educates caregivers about the potential benefits and limitations of genetic testing, detailing his approach to educating them before testing, how he guides them in interpreting results and transitioning to clinical management afterward, and the role of genetic counseling, including when to refer to a genetic specialist; he also provides key takeaways on the role and value of genetic testing for pediatric epilepsy and discusses how providers should utilize next-generation sequencing (NGS) moving forward.
Advertisement
Episodes in this series
- Please describe how you counsel and educate caretakers regarding the potential benefits and limitations of testing.
- How do you approach educating and counseling caregivers before genetic testing?
- After genetic testing, how do you counsel caregivers when interpreting results and shifting to clinical management?
- Please speak about the role of genetic counseling and when to refer to a genetic specialist.
- Please provide your key takeaways on the role and value of genetic testing for pediatric epilepsy.
- How should providers utilize NGS moving forward?
Advertisement
Related to this article
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of MDS!
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
A new Bayesian network meta-analysis found nipocalimab's serious adverse event rates compared favorably with other gMG therapies, while overall adverse event rates were comparable.
An updated open-label extension analysis and new MRI data from the phase 3 EPIDYS trial, presented at the 2026 AANEM Annual Meeting, add to the evidence for givinostat's long-term effects on disease progression.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
2
2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS
3
Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype
4
Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows
5